DRI-C21041

• Description :

  DRI-C21041 is a CD40/CD40L interaction inhibitor, with an IC50 of 0.31 μM. DRI-C21041 inhibits the immune response induced by alloantigen[1].

• UNSPSC :

  12352005

• Target :

  TNF Receptor

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/dri-c21041.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=S(C1=C2C(NC(C3=CC=C(C4=CC=C(NC(C5=CC=C([N+]([O-])=O)C=C5)=O)C=C4)C=C3)=O)=CC=CC2=CC=C1)(O)=O

• Molecular Formula :

  C30H21N3O7S

• Molecular Weight :

  567.57

• References & Citations :

  [1]Lu H, et, al. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020 Sep 23;5 (1) :213.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  TNFRSF5/CD40

• CAS Number :

  [2101765-78-8]